Drug intelligence / Profile preview

azathioprine + prednisolone + tacrolimus

Development stage: Unknown
Lead developer: GSK
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

A combination immunosuppressive regimen used primarily in solid organ transplantation to prevent rejection. This triple therapy combines different mechanisms of action: - **Tacrolimus** inhibits calcineurin, preventing T-cell activation and proliferation - **Prednisolone** is a corticosteroid that suppresses inflammation and immune response - **Azathioprine** is an antimetabolite that interferes with DNA synthesis in rapidly dividing cells, including immune cells This combination has been studied in various transplant settings including kidney, liver, and heart transplantation.

Targets

RAC1 (Rac family small GTPase 1)PPAT (Amidophosphoribosyltransferase)GR (Glucocorticoid receptor)MR (Mineralocorticoid receptor)

Beyond the preview

Go deeper on azathioprine + prednisolone + tacrolimus.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on azathioprine + prednisolone + tacrolimus.

Explore the full profile